Search

Background: In infants born weighing ≤500 g, little has been studied about the association between neurodevelopmental prognosis and growth. This study aimed to evaluate the association between neurodevelopmental impairment (NDI) and z‐scores of physical measurements in infants born weighing ≤500 g. Methods: A single‐center, retrospective cohort study in a level IV neonatal intensive care unit in Japan. Infants born weighing ≤500 g between 2010 and 2019 were eligible. Z‐scores in weight, length/height, and head circumference at birth, due date (or discharge), 6 and 18 months of corrected age, and 3 years of age were compared between infants with and without NDI at 3 years of age. Three infants with severe intraventricular hemorrhage or periventricular leukomalacia were excluded from the comparison analyses. NDI was defined as having a developmental quotient of ≤70, cerebral palsy, visual impairment, or hearing impairment. Results: Of 22 eligible infants, the incidence of NDI at 3 years of age was 54.5%. The z‐score was significantly smaller in the NDI group (n = 10) than that in the non‐NDI group (n = 9) in head circumference at birth (median, −1.94 vs. −0.75; Z = 0.54; p = 0.020), and in height at 18 months of corrected age (median, −2.84 vs. −1.79; Z = 0.58; p = 0.013) and 3 years of age (median, −2.02 vs. −1.21; Z = 0.47; p = 0.046). Conclusions: NDI at 3 years of age was associated with a small head circumference z‐score at birth, height at 18 months of corrected age, and height at 3 years of age in infants born weighing ≤500 g. [ABSTRACT FROM AUTHOR]

Background: Children born small for gestational age (SGA), particularly when associated with an extremely low birthweight (ELBW), have a higher risk of renal dysfunction. Growth hormone (GH) treatment is used to treat short‐statured children born SGA; however, its effects on renal function remain elusive, especially in those born SGA with ELBW. Methods: Short‐statured children born SGA (N = 42) were included. Subjects were subdivided into two groups based on their birthweight: the ELBW group (N = 15) with a birthweight of <1,000 g, and the non‐ELBW group (N = 27) with birthweights ranging between 1,000 and 2,500 g. The creatinine‐based estimated glomerular filtration rates (eGFR) before (pre‐eGFR) and 5 years after GH treatment (post‐eGFR) were compared. Correlations between eGFR, anthropometric, or birth parameters, and cumulative GH dose were evaluated using Spearman's rank correlation coefficient. Results: The ELBW group had a lower pre‐ and post‐eGFR than the non‐ELBW group. Five‐year GH treatment did not significantly reduce eGFR in either group. Post‐eGFR was positively associated with gestational week and birthweight. However, the cumulative GH dose was not correlated with pre‐eGFR, post‐eGFR, or percentage change in eGFR (%ΔeGFR). The change in bodyweight standard deviation score during GH treatment was positively correlated with %ΔeGFR in the ELBW group. Conclusions: The current results indicated that GH treatment was unlikely a risk for the reduction in eGFR in short‐statured children born SGA. However, eGFR should be carefully monitored, especially in those born SGA with ELBW because these subjects had lower eGFR than non‐ELBW subjects. [ABSTRACT FROM AUTHOR]

Background: The effectiveness of growth hormone (GH) treatment for height gain in short‐stature children born small for gestational age (SGA) with extremely low birthweight (ELBW; birthweight <1,000 g) remains largely unknown. Methods: In study 1, 35 prepubertal Japanese children born SGA with ELBW were categorized into three groups based on the presence or absence of catch‐up growth by age 3 (CU(+) and CU(−), respectively) and GH treatment (GH(+) and GH(−), respectively). Height standard deviation (SD) scores (HT‐SDS) in the CU−/GH+ group (n = 19) were compared with those in the age‐matched CU+/GH− (n = 9) and CU−/GH‐ groups (n = 7). In study 2, 66 prepubertal Japanese SGA children treated with GH were divided into three groups by birthweight: <1,000 g (n = 19), 1,000–2,000 g (n = 20), and >2,000 g (n = 27). Changes in HT‐SDS during the initial 3 years of GH treatment were compared among the three groups. Results: In study 1, the mean HT‐SDS in the CU−/GH+ group (−1.15 SD) was similar to that in the CU+/GH‐ group (−1.39 SD) but higher than that in the CU−/GH− group (−2.24 SD). In study 2, GH achieved a height gain of +1.62 SD in the ELBW group, which was similar to that in the other groups (1,000–2,000 g: +1.46 SD, >2,000 g: +1.53 SD). Conclusions: Growth hormone treatment in short‐stature children born SGA with ELBW increased HT‐SDS, which was similar to that in SGA children born with a birthweight ≥1,000 g. These results indicate that GH treatment may be an effective approach to promote adequate growth recovery for short‐stature children born SGA with ELBW. [ABSTRACT FROM AUTHOR]